# EDGAR Filing Document

**Accession Number:** 0001872529
**File Stem:** 0001213900-23-003870
**Filing Date:** 2023-1
**Character Count:** 86010
**Document Hash:** 3586b1bd267b99a04bc8edbba4e48661
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-003870.hdr.sgml**: 20230120

**ACCESSION NUMBER**: 0001213900-23-003870

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 8

**CONFORMED PERIOD OF REPORT**: 20230120

**FILED AS OF DATE**: 20230120

**DATE AS OF CHANGE**: 20230119

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MDxHealth SA
- **CENTRAL INDEX KEY:** 0001872529
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** C9

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40996
- **FILM NUMBER:** 23538701

**BUSINESS ADDRESS:**
- **STREET 1:** CAP BUSINESS CENTER
- **STREET 2:** RUE D'ABHOOZ, 31, B-4040
- **CITY:** HERSTAL
- **STATE:** C9
- **ZIP:** 00000
- **BUSINESS PHONE:** 949-271-9221

**MAIL ADDRESS:**
- **STREET 1:** CAP BUSINESS CENTER
- **STREET 2:** RUE D'ABHOOZ, 31, B-4040
- **CITY:** HERSTAL
- **STATE:** C9
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MDx Health SA
- **DATE OF NAME CHANGE:** 20210713

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE**

**SECURITIES EXCHANGE ACT OF 1934**

**For the month of January 2023**

**Commission File Number 001-40996**

**MDXHEALTH SA**

(Translation of registrant's name into English)

CAP Business Center

Zone Industrielle des Hauts-Sarts

4040 Herstal, Belgium

+32 4 257 70 21

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

**Note**: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

**Note**: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

**MDXHEALTH SA**

**Press Release**

On January 20, 2023, MDxHealth SA (the "Company") issued a press release, a copy of which is attached hereto as Exhibit 99.1 (the "Press Release").

*The information in the attached Exhibit 99.1 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall they be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.*

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| 99.1 | [Press Release, dated January 20, 2023.](ea171931ex99-1_mdxhealth.htm) |

---

**Financial Statements for the Nine Months Ended September 30, 2022**

Filed herewith as Exhibit 99.2 are the unaudited interim condensed financial statements of the Company for the nine months ended September 30, 2022 (the "Financial Statements").

As noted in the Press Release, the Financial Statements reflect certain corrections made to the financial information for the nine months ended September 30, 2022, previously reported by the Company in a press release issued on October 27, 2022 (the "Press Release").

In connection with the preparation of the Financial Statements the Company identified a material weakness in its internal control over financial reporting at September 30, 2022 related to ineffective design and operation of its interim financial close and reporting controls. More specifically, internal control over financial reporting procedures used in connection with the preparation of the financial information contained in the Press Release failed to identify a number of cut-off errors. These cut-off errors have been corrected in the Financial Statements. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of a company's annual or interim financial statements will not be prevented or detected on a timely basis. Although the Company is taking action to remediate these issues, including engaging an outside IFRS consulting firm to assist the Company with its interim closing process, these efforts may not be sufficient to avoid similar material weaknesses in the future. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur remediation costs. To the extent the Company is unable to remediate this material weakness or is unable to identify future material weaknesses, investors could lose confidence in the accuracy or completeness of the Company's reported financial information, which could have a negative effect on the trading price of the Company's ADSs.

**Oncotype DX® GPS Acquisition**

On August 2, 2022, the Company entered into an asset purchase agreement with Genomic Health, Inc., a subsidiary of Exact Sciences Corporation ("Exact Sciences"), to acquire the Oncotype DX® GPS (Genomic Prostate Score® or GPS<sup>TM</sup>) test from Exact Sciences and hired most of its team of urology sales and marketing professionals.

Filed herewith as Exhibit 99.3 is revised unaudited combined pro forma condensed balance sheet information regarding the Company and Oncotype DX GPS Prostate Score® Test as of June 30, 2022, and revised unaudited combined pro forma statement of operations regarding the Company and Oncotype DX GPS Prostate Score® Test for the year ended December 31, 2021 and for the six months ended June 30, 2022, respectively. As noted in the Press Release, this pro forma financial information reflects certain corrections made to the pro forma financial information previously filed as Exhibit 99.2 to the Form 6-K filed by the Company on December 19, 2022.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| 99.2 | [Unaudited interim condensed financial statements of the Company for the nine months ended September 30, 2022](ea171931ex99-2_mdxhealth.htm) |
| 99.3 | [Revised Unaudited combined pro forma condensed balance sheets of the Company and Oncotype DX GPS Prostate Score® Test as of June 30, 2022, and the revised unaudited combined pro forma statement of operations of the Company and Oncotype DX GPS Prostate Score® Test for the year ended December 31, 2021 and for the six months ended June 30, 2022](ea171931ex99-3_mdxhealth.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **MDXHEALTH SA** | **MDXHEALTH SA** | **MDXHEALTH SA** |
| Date: January 20, 2023 | By: | /s/ Michael McGarrity | /s/ Michael McGarrity |
|  |  | Name: | Michael McGarrity |
|  |  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**NEWS RELEASE –REGULATED INFORMATION**

**20 JANUARY 2023, 1:00 am ET / 7:00 am CET**

**MDxHealth Provides Updated and Supplemental Financial Information** 

**Related to Acquisition of GPS Test**

**IRVINE, CA, and HERSTAL, BELGIUM** – January 20, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today provided supplemental information related to its acquisition of the Oncotype DX<sup>®</sup> GPS (Genomic Prostate Score<sup>®</sup>) test on August 2, 2022 (the "GPS Test Acquisition"), from Genomic Health, Inc., a subsidiary of Exact Sciences Corporation ("Exact Sciences").

**GPS Test Acquisition Integration**

As part of its ongoing post-acquisition integration collaboration with Exact Sciences, the Company in Q4 2022 transitioned all GPS test ordering processes from Exact Sciences to MDxHealth systems, including a transition to its online physician ordering portal. In addition, mdxhealth completed its integration and restructuring of the urology focused sales and customer success teams.

**Financial Statements for the period ended September 30, 2022** 

In the course of its annual closing process for 2022, the Company determined that certain transaction-related revisions were appropriate to account for the timing of GPS Test Acquisition expenses, as well as the timing of financing expenses related to the Company's replacement of its debt facility with an affiliate of Innovatus Capital Partners, LLC coincident with the GPS Test Acquisition. These revisions did not affect the Company's reported cash balance as of, or reported revenues for the periods ended, September 30, 2022, or December 31, 2022. Pursuant to these revisions, operating expenses for Q3 2022 increased by approximately $3.8 million, primarily comprised of $3.2 million in GPS Test Acquisition related non-recurring expenses (previously recorded in Q4 2022) and $0.5 million in amortization charges related to the GPS intangible assets. In addition, one-time additional financial expense of approximately $1.2 million related to replacing the Company's debt facility was recorded.

As part of the above updates, the Company has prepared condensed interim financial statements with associated footnotes for the nine-month period ended September 30, 2022, filed as Exhibit 99.2 to a Form 6-K filed with the Securities and Exchange Commission. The condensed interim financial statements for the nine-month period ended September 30, 2022, are also available on the Company's website. These financial statements provide detailed disclosures, among other things, on the GPS Test Acquisition as well as the new debt facility with Innovatus which replaced the Kreos debt facility.

**Pro forma Financial Statements**

To reflect the foregoing updates related to the GPS Test Acquisition and Innovatus debt facility, the Company has also filed as Exhibit 99.3 to Form 6-K with the Securities and Exchange Commission, updated unaudited pro forma combined financial information as of and for the six months ended June 30, 2022, and for the year ended December 31, 2021.

The pro forma information has been prepared by our management and it may not be indicative of the results that actually would have occurred had the transaction been in effect on the dates indicated, nor does it purport to indicate the results that may be obtained in the future. The pro forma information is based on provisional amounts allocated by management to various assets and liabilities acquired and may be eventually different than currently presented.

**About mdxhealth** **<sup>®</sup>** 

Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company's tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company's U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

**Financial information and auditor review**

The unaudited financial data for the three-month period ended September 30, 2022, referenced above, is derived from internal financial reports. The Company's statutory auditor, BDO Réviseurs d'Entreprises SRL, has confirmed that its review procedures with respect to the Company's condensed consolidated financial statements as of and for the nine-month period ended September 30, 2022, filed with the Securities and Exchange Commission as an exhibit to Form 6-K and prepared in accordance with the International Financial Reporting Standards as issued by the International Accounting Standards Board (IASB) and as adopted by the EU, have been substantially completed. The aforementioned condensed consolidated financial statements may be found on the Company's website at www.mdxhealth.com.

**For more information:** 

**mdxhealth**

info@mdxhealth.com

**LifeSci Advisors (IR & PR)**

US: +1 949 271 9223

ir@mdxhealth.com

***Forward-looking Statements***

 ****

*This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "potential," "expect," "will," "goal," "next," "potential," "aim," "explore," "forward," "future," and "believes" as well as similar expressions. Forward-looking statements contained in this release include, but are not limited to, statements regarding the acquisition of Oncotype DX<sup>®</sup> GPS prostate cancer business from Exact Sciences including statements regarding the anticipated benefits of the acquisition; statements regarding expected future operating results; statements regarding product development efforts; and statements regarding our strategies, positioning, resources, capabilities and expectations for future events or performance. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, product development efforts, our strategies, positioning, resources, capabilities and expectations for future events or performance. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: uncertainties associated with the coronavirus (COVID-19) pandemic, including its possible effects on our operations, and the demand for our products; our ability to successfully and profitably market our products; the acceptance of our products and services by healthcare providers; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; the possibility that the anticipated benefits from our business acquisitions like our acquisition of the Oncotype DX<sup>®</sup> GPS prostate cancer business will not be realized in full or at all or may take longer to realize than expected; and the amount and nature of competition for our products and services. Other important risks and uncertainties are described in the Risk Factors sections of our most recent Annual Report on Form 20-F and in our other reports filed with the Securities and Exchange Commission. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.*

 

 

***NOTE:*** *The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.*

 

**CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS** 

**<u>For the three months ended September 30, 2022</u>**

---

| | | |
|:---|:---|:---|
| In thousands of USD (except per share data) | **Jul-Sep<br> 2022** | **Jul-Sep<br> 2021** |
| Services | 11136 | 5482 |
| Licenses | 0 | 0 |
| Royalties and other revenues | 18 | 13 |
| **Revenues** | **11154** | **5495** |
| Cost of goods & services sold | (4931) | (2933) |
| **Gross Profit** | **6223** | **2562** |
| Research and development expenses | (2167) | (1504) |
| Selling and marketing expenses | (7771) | (4325) |
| General and administrative expenses | (8100) | (3813) |
| Other operating income, net | (115) | (71) |
| **Operating loss** | **(11930)** | **(7151)** |
| Financial expenses, net | (1701) | (470) |
| **Loss before income tax** | **(13631)** | **(7621)** |
| Income tax | 129 | 0 |
| **Loss for the period** | **(13502)** | **(7621)** |
| Basic and diluted loss per share | (0.08) | (0.06) |

---

**<u>For the nine months ended September 30, 2022</u>**

---

| | | |
|:---|:---|:---|
| In thousands of USD (except per share data) | **Jan-Sep<br> 2022** | **Jan-Sep<br> 2021** |
| Services | 24111 | 15944 |
| Licenses | 0 | 250 |
| Royalties and other revenues | 52 | 32 |
| **Revenues** | **24163** | **16226** |
| Cost of goods & services sold | (12168) | (8449) |
| **Gross Profit** | **11995** | **7777** |
| Research and development expenses | (5752) | (4327) |
| Selling and marketing expenses | (17619) | (12572) |
| General and administrative expenses | (17736) | (10552) |
| Other operating income, net | 159 | 80 |
| **Operating loss** | **(28953)** | **(19594)** |
| Financial expenses, net | (2781) | (1326) |
| **Loss before income tax** | **(31734)** | **(20920)** |
| Income tax | 128 | 0 |
| **Loss for the period** | **(31606)** | **(20920)** |
| Basic and diluted loss per share | (0.20) | (0.18) |

---

## Exhibit 99.2

**Exhibit 99.2**

&nbsp;&nbsp;![](ex99-2_001.jpg)

**INTERIM REPORT FOR THE <br> NINE MONTHS ENDED<br> SEPTEMBER 30, 2022**

**<u>**TABLE OF CONTENTS**</u>**

**I.** [**INTERIM MANAGEMENT REPORT**](#a_001) F- 2

**II.** [**INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MDXHEALTH SA**](#a_002) F- 3

1. [CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME](#a_003) F- 3

2. [CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION](#a_004) F- 4

3. [CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY](#a_005) F- 5

4. [CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS](#a_006) F- 6

5. [EXPLANATORY NOTES](#a_007) F- 7

**III.** [**CORPORATE INFORMATION**](#a_008) F-19

This Interim Report contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth SA and its wholly-owned subsidiaries (hereinafter "mdxhealth" or the "Company") and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: uncertainties associated with the coronavirus (COVID-19) pandemic, including its possible effects on our operations, and the demand for the Company's products; the Company's ability to successfully and profitably market its products; the acceptance of its products and services by healthcare providers; the willingness of health insurance companies and other payers to cover its products and services and adequately reimburse us for such products and services; and the amount and nature of competition for its products and services. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this Interim Report to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This Interim Report does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

**I. INTERIM MANAGEMENT REPORT**

**<u>Principal risks related to the business activities</u>**

The principal risks related to the MDxHealth's business activities have been outlined in the 2021 Annual Report, which is available on the internet at www.mdxhealth.com/investors/financials

**<u>Declaration of responsible persons</u>**

The Board of Directors of MDxHealth SA, represented by all its members, declares that, as far as it is aware, the financial statements in this Interim Report, made up according to the applicable standards for financial statements, give a true and fair view of the equity, financial position and the results of the company and its consolidated companies. The Board of Directors of MDxHealth SA, represented by all its members, further declares that this Interim Report gives a true and fair view on the information that has to be contained herein. The condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard (IAS) 34 (Interim Financial Reporting) as issued by the International Accounting Standards Board, or IASB, and as adopted by the EU.

**II. INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS OF MDXHEALTH SA**

**For the nine months ended September 30, 2022**

**1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME**

In thousands of USD (except per share data)

 ****

***Condensed unaudited consolidated statement of profit or loss***

---

| | | | |
|:---|:---|:---|:---|
|  | **Note** | **Jan-Sep<br> 2022** | **Jan-Sep<br> 2021** |
| Services | **5** | 24111 | 15944 |
| Licenses | **5** | 0 | 250 |
| Royalties and other revenues | **5** | 52 | 32 |
| **Revenues** |  | **24163** | **16226** |
| Cost of goods & services sold |  | (12168) | (8449) |
| **Gross Profit** |  | **11995** | **7777** |
| Research and development expenses |  | (5752) | (4327) |
| Selling and marketing expenses |  | (17619) | (12572) |
| General and administrative expenses |  | (17736) | (10552) |
| Other operating income, net |  | 159 | 80 |
| **Operating loss** |  | **(28953)** | **(19594)** |
| Financial income | **8** | 86 | 11 |
| Financial expenses | **8** | (2867) | (1337) |
| **Loss before income tax** |  | **(31734)** | **(20920)** |
| Income tax |  | 128 | 0 |
| **Loss for the period** |  | **(31606)** | **(20920)** |
| **Loss for the period attributable to the parent** |  | **(31606)** | **(20920)** |
| **Loss per share attributable to parent** |  |  |  |
| Basic and diluted |  | (0.20) | (0.18) |
| ***Condensed unaudited consolidated statement of other comprehensive income*** |  |  |  |
| **Loss for the period** |  | **(31606)** | **(20920)** |
| **Other comprehensive income** |  |  |  |
| *Items that will be reclassified to profit or loss:*<br> Exchange differences arising from translation of foreign operations |  | 693 | 123 |
| **Total other comprehensive income** |  | **693** | **123** |
| **Total comprehensive loss for the period (net of tax)** |  | **(30913)** | **(20797)** |

---

**2. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION**

*In thousands of USD*

---

| | | | |
|:---|:---|:---|:---|
| | **Note** | **as of**<br> **September 30,<br> 2022** | **as of**<br> **December 31, <br> 2021** |
| <br>**ASSETS** | | | |
| Goodwill | **3** | 29218 | 0 |
| Intangible assets | **6** | 46771 | 3448 |
| Property, plant and equipment |  | 2749 | 1671 |
| Right-of-use assets |  | 2923 | 3347 |
| **Non-current assets** |  | **81661** | **8466** |
| Inventories |  | 2528 | 1911 |
| Trade receivables | **9** | 9540 | 4582 |
| Prepaid expenses and other current assets |  | 1477 | 1615 |
| Cash and cash equivalents | **9** | 27368 | 58498 |
| **Current assets** |  | **40913** | **66606** |
| **Total assets** |  | **122574** | **75072** |
| **EQUITY** |  |  |  |
| Share capital |  | 133454 | 128454 |
| Issuance premium |  | 153177 | 153177 |
| Accumulated deficit |  | (275908) | (244302) |
| Share-based compensation |  | 11099 | 10607 |
| Foreign currency translation reserves |  | (344) | (1037) |
| **Total equity** |  | **21478** | **46899** |
| **LIABILITIES** |  |  |  |
| Loans and borrowings | **7** | 34642 | 7651 |
| Lease liabilities | **7** | 2256 | 2624 |
| Other non-current financial liabilities | **7/9** | 44923 | 1466 |
| **Non-current liabilities** |  | **81821** | **11741** |
| Loans and borrowings | **7** | 615 | 4441 |
| Lease liabilities | **7** | 801 | 840 |
| Trade payables | **9** | 12019 | 7455 |
| Other current liabilities |  | 3556 | 2735 |
| Other current financial liabilities | **7/9** | 2284 | 961 |
| **Current liabilities** |  | **19275** | **16432** |
| **Total liabilities** |  | **101096** | **28173** |
| **Total equity and liabilities** |  | **122574** | **75072** |

---

**3. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**

<br> Attributable to owners of MDxHealth SA

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **In thousands of USD, except number of shares** | **Number of<br> shares** | **Share<br> capital and<br> issuance<br> premium** | **Accumulated<br> deficit** | **Share-based<br> compensation** | **Foreign<br> currency<br> translation<br> reserves** | **Total <br> equity** |
| **Balance at January 1, 2021** | **90691449** | **213065** | **(215300)** | **9385** | **(1301)** | **5849** |
| Loss for the period |  |  | (20920) |  |  | **(20920)** |
| Other comprehensive income |  |  |  |  | 123 | **123** |
| **Total comprehensive income for the period** |  |  | **(20920)** |  | **123** | **(20797)** |
| *Transactions with owners in their capacity as owners:* |  |  |  |  |  |  |
| Issuance of shares, net of transaction costs | 27777777 | 28336 |  |  |  | **28336** |
| Share-based compensation |  |  |  | 667 |  | **667** |
| **Balance at September 30, 2021** | **118469226** | **241401** | **(236220)** | **10052** | **(1178)** | **14055** |
| **Balance at January 1, 2022** | **155969226** | **281631** | **(244302)** | **10607** | **(1037)** | **46899** |
| Loss for the period |  |  | **(31606)** |  |  | **(31606)** |
| Other comprehensive income |  |  |  |  | **693** | **693** |
| **Total comprehensive income for the period** |  |  | (31606) |  | 693 | **(30913)** |
| *Transactions with owners in their capacity as owners:* |  |  |  |  |  |  |
| Issuance of shares as part of GPS acquisition | 6911710 | 5000 |  |  |  | **5000** |
| Share-based compensation |  |  |  | **492** |  | **492** |
| **Balance at September 30, 2022** | **162880936** | **286631** | **(275908)** | **11099** | **(344)** | **21478** |

---

**4. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS**

*In thousands of USD*

---

| | | | |
|:---|:---|:---|:---|
|  | **Note** | **Jan-Sep** <br> **2022** | **Jan-Sep** <br> **2021** |
| **CASH FLOWS FROM OPERATING ACTIVITIES** | | | |
| Operating loss |  | (28953) | (19594) |
| Depreciation and amortization |  | 2873 | 2232 |
| Share-based compensation |  | 492 | 667 |
| Non-cash fair value change |  | 107 | 0 |
| Non-cash foreign exchange rate change |  | (125) | (866) |
| Other non-cash transactions |  | 219 | 0 |
| **Cash generated from operations before working capital changes** |  | **(25387)** | **(17561)** |
| **Changes in operating assets and liabilities** |  |  |  |
| Increase in inventories |  | (617) | (42) |
| Increase in receivables |  | (4820) | (679) |
| Increase in payables |  | 6429 | 1319 |
| **Net cash outflow from operating activities** |  | **(24395)** | **(16963)** |
| **CASH FLOWS FROM INVESTING ACTIVITIES** |  |  |  |
| Purchase of property, plant and equipment |  | (1457) | (653) |
| Purchase of intangible assets |  | (465) | 0 |
| Acquisition of Genomic Prostate Score business | **3** | (25000) | 0 |
| **Net cash outflow from investing activities** |  | **(26922)** | **(653)** |
| **CASH FLOWS FROM FINANCING ACTIVITIES** |  |  |  |
| Proceeds from issuance of shares, net of transaction costs |  | 0 | 28336 |
| Proceeds from loan obligation | **7** | 33264 | 0 |
| Repayment of loan obligation and debt extinguishment costs | **7** | (10758) | 0 |
| Payment of lease liability | **7** | (1009) | (754) |
| Payment of interest |  | (671) | (767) |
| Interests received |  | 35 | 11 |
| **Net cash inflow from financing activities** |  | **20861** | **26826** |
| **Net increase in cash and cash equivalents** |  | **(30456)** | **9210** |
| **Cash and cash equivalents at beginning of the period** |  | **58498** | **15953** |
| Effect of exchange rates |  | (674) | (458) |
| **Cash and cash equivalents at end of the period** |  | **27368** | **24705** |

---

**5. EXPLANATORY NOTES**

**Accounting policies**

**1. Basis of preparation**

MDxHealth, SA together with its subsidiaries are herein referred to as "MDxHealth" or the "Company". MDxHealth is a company domiciled in Belgium, with offices and labs in the United States and The Netherlands. The reporting and functional currency of the Company is the U.S. Dollar.

The condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard (IAS) 34 – Interim Financial Reporting, as issued by the International Accounting Standards Board, or IASB, and as adopted by the EU.

These interim consolidated financial statements do not include all the information required for full annual financial statements and should be read in conjunction with the consolidated financial statements of the Company as of, and for the year ended, December 31, 2021.

The Company ended the period with $27.4 million in cash and cash equivalents as of September 30, 2022, and continued to incur losses. The Company is expecting continued losses and negative operating cash flows in the coming twelve months. Taking into account the above financial situation, the most recent business plan, which includes the newly acquired Genomic Prostate Score<sup>®</sup> (GPS) test (formerly Oncotype DX GPS), the respective contingent consideration earn-outs payable in 2024, 2025 and 2026 relating to the above acquisition (which are further detailed in Note 3), as well as the newly obtained Innovatus debt facility, which provides for an additional $35 million in proceeds under certain conditions (which are further detailed in Note 7), the Company believes that it has sufficient cash to be able to continue its operations for at least the next twelve months from the date of issuance of these financial statements, and accordingly has prepared the consolidated financial statements assuming that it will continue as a going concern. This assessment is based on forecasts and projections within management's most recent business plan as well as the Company's expected ability to realize cost reductions should these forecasts and projections not be met.

**2. Significant accounting policies, use of judgments and estimates**

The Company applies the International Financial Reporting Standards (IFRS) as issued by the IASB and as adopted by the EU. The same accounting policies, presentation and methods of computation have been followed in these condensed financial statements as were applied in the preparation of the Company's financial statements for the year ended December 31, 2021. No amendments to existing standards that became applicable as from January 1, 2022, have a material impact on the consolidated financial statements or accounting policies.

The preparation of the interim condensed financial statements in compliance with IAS 34 requires the use of certain critical accounting estimates. It also requires the Company's management to exercise judgment in applying the Company's accounting policies. Except for the new estimates and judgements made following the GPS acquisition and the new financing obtained from Innovatus, the Company has applied the same accounting policies and there have been no material revisions to the nature and amount of estimates and judgments in its interim condensed financial statements.

As part of the preliminary purchase price allocation associated with the GPS acquisition on August 2, 2022, the Company has applied new estimates and judgement with respect to weighted-average cost of capital (WACC), probability contingent consideration payments, and the valuation of the identified intangible assets. The acquired intellectual property of the GPS intangible asset is considered to have a useful life of 15 years and will be amortized accordingly. Refer to Note 3 for further details.

The new debt facility from Innovatus Capital Partners, LLC ("Innovatus") has been accounted for as a hybrid financial instrument, which includes a host financial liability and an embedded derivative call option to convert up to 15% of the aggregate outstanding principal into equity at a fixed price of $11.21 per ADS. Both the host financial liability and the embedded derivative call option are accounted for separately. The derivative (American) call option is valued at fair value using a binomial tree option pricing model whereby the fair value is based on the actual stock price and the estimated volatility of the Company's ADS on Nasdaq since the Company's IPO on November 4, 2021, through the valuation date. The volatility measured at August 2, 2022, which was the closing date of the Innovatus debt facility, was 62.85% and at September 30, 2022 was 65.09%. Refer to Note 7 for further details regarding the Innovatus debt facility.

**3. Business combinations**

*<u>Acquisition of Genomic Prostate Score<sup>®</sup> (GPS) test (formerly Oncotype DX GPS) from Exact Sciences</u>*

On August 2, 2022, the Company announced it has entered into an agreement with Genomic Health, Inc., a subsidiary of Exact Sciences Corporation ("Exact Sciences"), to acquire the GPS test from Exact Sciences. MDxHealth acquired GPS in order to expand its menu of tests targeted into urology and prostate cancer and in order to position the Company as one of the leaders in the urology and prostate cancer space with one of the most comprehensive menus of precision diagnostics.

Under the terms of the agreement, the Company acquired the GPS prostate cancer business of Exact Sciences for an aggregate purchase price of up to $100 million, of which an amount of $25 million was paid in cash and an amount of $5 million was settled through the delivery of 691,171 American Depositary Shares ("ADSs") of the Company, at a price per ADS of $7.23. Following the closing, which took place on August 2, 2022, an additional aggregate earn-out amount of up to $70 million is to be paid by the Company to Exact Sciences over a three year period, commencing in 2024, in tranches equal to a portion of the annual revenues attributable to the GPS prostate cancer business for the preceding fiscal year; provided, in each instance, that such revenues exceed certain minimum revenue milestones for such fiscal year.

At the option of MDxHealth, the earn-out amounts can be settled in cash or through the issuance of additional ADSs of the Company (valued in function of a volume weighted average trading price of the Company's shares at the end of the relevant earn-out period) to Exact Sciences, provided that the aggregate number of shares representing the ADSs held by Exact Sciences shall not exceed more than 5% of the outstanding shares of the MDxHealth.

The Acquisition was accounted for under the acquisition method of accounting and is being treated as a business combination in accordance with IFRS given that there are inputs from the intellectual property and customers acquired, a substantive process, consisting of a workforce that was hired from Exact Sciences, which allows the Company to generate outputs as from day 1 of the acquisition. The purchase price was preliminarily allocated based on the estimated fair value of net assets acquired and liabilities assumed at the date of the acquisition. The preliminary purchase price allocation is subject to further refinement and may require adjustments to arrive at the final purchase price allocation. The Company expects to finalize the purchase price allocation within the context of its 2022 yearend reporting.

The acquisition consideration was comprised of (in thousands USD):

---

| | |
|:---|:---|
| Cash | $25000 |
| Stock | 5000 |
| Contingent consideration | 43777 |
| &nbsp;&nbsp;&nbsp;Total acquisition consideration | $73777 |

---

On a preliminary basis, and until the purchase price allocation has been finalized, the purchase price in excess of the fair value of net assets acquired, has been considered as residual Goodwill for an amount of $29.2 million.

The fair value of the identifiable assets at the date of acquisition were:

---

| | | | |
|:---|:---|:---|:---|
| In thousands USD<br> **As of September 30, 2022** | **Carrying<br> value at<br> acquisition<br> date** | **Fair value<br> adjustments** | **Fair value at<br> acquisition<br> date** |
| Intangible assets IP / Brand |  | 44559 | 44.559 |
| **Total identified assets** |  | **44559** | **44559** |
| Goodwill |  | 29218 | 29218 |
| **Acquisition price** |  | **-** | **73777** |

---

We have performed a preliminary fair value analysis of the business combination, with corresponding adjustments to the intangible assets. The items with the highest likelihood of changing upon the completion of the valuation process include IP/brand and Goodwill.

The accounting for the business combination resulted in fair values at date of acquisition of $44.6 million for the IP and brand, based on the relief-from-royalty valuation method, with a royalty rate of 12.40% and a remaining useful life of 15 years. The discount rate (post-tax WACC) used for the valuation was set at 16.01%. The goodwill recognized is primarily attributable to the trained and knowledgeable workforce and to the expected synergies that will be realized at level of operations, existing customer base, and sales & marketing. Based upon a sensitivity analysis, a change by -1.0% in the royalty rate would result in a decrease of the IP and brand of by $3.6 million.

Following the closing, an additional aggregate earn-out amount of up to $70 million is to be paid by MDxHealth to Exact Sciences upon achievement of certain revenue milestones related to fiscal years 2023 through 2025. On a preliminary basis the contingent consideration has been assessed at $43.8 million. The liability recognized reflects a probability-weighted estimate at the current net present value at the date of acquisition, which is expected to become payable, as further detailed in Note 9. Future fair value adjustments to this contingent consideration liability will be recognized in the statement of profit or loss, after finalization of the purchase price allocation.

The total acquisition-related costs recognized as an expense in the general & administration costs are $3.5 million.

The GPS acquisition has contributed $3.4 million to the Company's consolidated revenues for the period ended September 30, 2022. Per the unaudited special purpose financial statements for the GPS business filed as exhibit 99.1 to Form 6-K on December 19, 2022, the GPS business generated revenues of $18.5 million for the six-month period ended June 30, 2022.

The Company financed the acquisition in part through a $35 million loan and security agreement with an affiliate of Innovatus Capital Partners, LLC ("Innovatus"), which replaced the Company's existing EUR 9 million debt facility with Kreos Capital ("Kreos"). Refer to Note 7 for further details.

 

**4. Significant events and transactions**

 

*<u>Acquisition of GPS test</u>*

Refer to Note 3 – Business combinations, for further information on the acquisition of the GPS test as well as to Note 7 – Loans, Borrowings and Lease Liabilities for information on related debt transactions with Innovatus and Kreos.

 

*<u>COVID-19</u>*

The COVID-19 outbreak has impacted management's estimates, judgments and assumptions, and could impact the Company's ability to develop business, conduct operations, and obtain components used in its business. The situation is continuously evolving, therefore the extent to which the COVID-19 outbreak will continue to impact business and the economy is highly uncertain and is extremely difficult to predict. Accordingly, the Company cannot accurately predict the extent to which its 2022 financial condition and results of operations will further be affected.

The areas where assumptions and estimation uncertainties in the financial statements related to the COVID-19 outbreak have potentially the most significant effect in 2021 are related to the Company's ability to continue as a going concern, revenue recognition, impairment testing, and recognized fair value measurements.

In light of the COVID-19 pandemic, management took every precaution necessary to stay safe and to ensure tests remain accessible to patients who need them. These precautions included:

● Following all CDC (Centers for Disease Control and Prevention) recommendations for maintaining a healthy work environment

● Directing many of the office staff to work remotely. Those who work in the office are following regulatory guidelines and recommendations to ensure their safety

● Conducting meetings virtually

● Restricting staff travel

**5. Segment information**

The Company does not distinguish different business segments since most revenues are generated from clinical laboratory service testing. However, the Company does distinguish different geographical operating segments based on revenue since the revenues are generated both in United States of America and Europe.

Total product revenue and non-current assets are shown below as a percentage by geography:

---

| | |
|:---|:---|
| ![](ex99-2_002.jpg) | ![](ex99-2_003.jpg) |

---

**Segment revenues**

As of September 30, 2022, the Company earned 100% of its revenue from external customers from its clinical laboratory testing services and out-licensing of intellectual property. As of September 30, 2022, the clinical laboratory testing in the U.S. CLIA laboratory represented 98.9% of the Company's revenue (first nine months of 2021: 96.2%), while the out-licensing of intellectual property revenue and grant income in Europe represented less than 1% (first nine months of 2021: 1.7%).

The Company has one payor responsible for more than 40% of the Company's revenues over the period, represented by Medicare.

The amount of its revenue from external customers broken down by location from the customers is shown in the table below:

---

| | | |
|:---|:---|:---|
| *In thousands of USD* | **Jan-Sep<br> 2022** | **Jan-Sep<br> 2021** |
| United States of America | 23952 | 15889 |
| The Netherlands | 62 | 138 |
| Rest of the EU | 143 | 191 |
| Rest of the world | 6 | 8 |
| **Total segment revenue** | **24163** | **16226** |

---

The amount of its revenue by category is already presented on the face of the consolidated statement of income.

As of September 30, 2022, 95% of the non-current assets were located in the U.S. (Sept 30, 2021: 42%) and the remaining 5% were located in Europe (Sept 30, 2021: 58%). The increase in non-current assets located in the U.S. is mainly due to acquired intangible assets in the GPS business combination as detailed in Note 3.

**6. Intangible assets**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *Balance at the closing date of*<br> In thousands of USD | **September 30, 2022** | **September 30, 2022** | **September 30, 2022** | **September 30, 2022** | **September 30, 2022** | **December 31, <br> 2021** |
|  | **Intellectual<br> and<br> property<br> rights &<br> software<br> licenses** | **Internally-<br> developed<br> intangible<br> assets** | **Externally-<br> acquired<br> intellectual<br> property<br> GPS** | **Externally-<br> developed<br> in-process<br> R&D** | **Total** | **Total** |
| **Gross value** |  |  |  |  |  |  |
| **At January 1, 2022** | **5134** | **9323** | **4500** | **3300** | **22257** | **22257** |
| Additions |  |  | 465 |  | 465 |  |
| Additions through business combination (Note 3) |  |  | 44559 |  | 44559 |  |
| **Gross value at September 30, 2022** | **5134** | **9323** | **49524** | **3300** | **67281** | **22257** |
| **Accumulated amortization and impairment** |  |  |  |  |  |  |
| **At January 1, 2022** | **(4910)** | **(7736)** | **(2863)** | **(3300)** | **(18809)** | **(17199)** |
| Additions | (168) | (695) | (838) |  | (1701) | (1610) |
| **Accumulated amortization and impairment at September 30, 2022** | **(5078)** | **(8431)** | **(3701)** | **(3300)** | **(20510)** | **(18809)** |
| **Net value at September 30, 2022** | **56** | **892** | **45823** | **0** | **46771** | **3448** |

---

**7. Loans, Borrowings and Other financial liabilities**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Loans and** <br> **borrowings** | **Loans and** <br> **borrowings** | **Loans and** <br> **borrowings** | **Other financial liabilities** | **Other financial liabilities** | **Other financial liabilities** |
| <br>***In thousands of USD<br> Balance at the closing date of***  | ***Sept 30,<br> 2022*** | ***December 31,<br> 2021*** | ***Sept 30,<br> 2021*** | ***Sept 30,<br> 2022*** | ***December 31,<br> 2021*** | ***Sept 30,<br> 2021*** |
| **Beginning balance** | **12092** | **13097** | **13097** | **2427** | **1599** | **1599** |
| **Cash movements** |  |  |  |  |  |  |
| Loans and borrowings repaid | (10758) |  |  |  |  |  |
| Loans and borrowings received | 33265 |  |  | 1026 |  |  |
| **Non-cash movements** |  |  |  |  |  |  |
| GPS contingent consideration |  |  |  | 43777 |  |  |
| Reclassification <sup>(1)</sup> |  | (773) |  |  | 773 |  |
| Kreos effective interest rate adjustment and extinguishment costs | 1328 | 536 | 187 | 170 | 194 | 118 |
| Innovatus - effective interest rate adjustment | 233 |  |  |  |  |  |
| Foreign exchange rate impact / other | (903) | (768) | (627) | (86) | (59) |  |
| Fair value changes through profit and loss |  |  |  | (107) | (80) | (49) |
| **Balance at the closing date** | **35257** | **12092** | **12657** | **47207** | **2427** | **1668** |

---

*(1)* *Reclassification of the fair value of the derivative financial liability of the initial drawdown fee to be presented separately* 

---

| | | | |
|:---|:---|:---|:---|
| | ***Lease liabilities*** | ***Lease liabilities*** | ***Lease liabilities*** |
| <br>*In thousands of USD<br> Balance at the closing date of* | ***Sept 30,<br> 2022*** | ***December 31, <br> 2021*** | ***Sept 30,<br> 2021*** |
| **Beginning balance** | **3464** | **2774** | **2774** |
| **Cash movements** |  |  |  |
| Repayment of lease liabilities | (1009) | (1057) | (754) |
| **Non-cash movements** |  |  |  |
| Interest accretion | 234 | 229 | 152 |
| New leases | 368 | 1518 | 0 |
| **Balance at the closing date** | **3057** | **3464** | **2172** |

---

***Innovatus debt facility***

 

On August 2, 2022, the Company entered into a $70 million loan and security agreement with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), which loan also replaced the Company's EUR 9 million debt facility with Kreos Capital. At closing, an amount of $35 million was drawn, with an additional $35 million remaining available as a $20 million term B loan and a $15 million term C loan that can be drawn in 2024 and 2025 respectively, subject to certain conditions. The loans are secured by assets of the Group including intellectual property rights. Remaining proceeds of the loans will be used for working capital purposes and to fund general business requirements.

The loans accrue interest at a floating per annum rate equal to the sum of (a) the greater of (i) the prime rate published in The Wall Street Journal in the "Money Rates" section or (ii) 4.00%, plus (b) 4.25%, and require interest-only payments for the initial four years. At the election of the Company, a portion of the interest may be payable in-kind by adding an amount equal to 2.25% of the outstanding principal amount to the then outstanding principal balance on a monthly basis until August 2, 2025. The loans mature on August 2, 2027. The lenders shall have the right to convert, prior to August 2, 2025, up to 15% of the outstanding principal amount of the loans into ADSs of the Company at a price per ADS equal to $11.21, reflecting a substantial premium to the trading price prior to the announcement of the acquisition. Amounts converted into ADSs of the Company will be reduced from the principal amount outstanding under the loan. Notable fees payable to Innovatus consist of a facility fee equal to 1% of the total loan commitment, due on the funding date of the relevant loans, and an end-of-loan fee equal to 5% of the amount drawn, payable upon final repayment of the relevant loans.

The Innovatus debt facility has been accounted for as a hybrid financial instrument which includes a host financial liability as well as an embedded derivative financial instrument being an equity conversion call option at a fixed rate of up to 15% of the aggregate outstanding principal amount through August 2, 2025.

The embedded derivative is not considered to be closely related to the host financial liability given the differences in economics and risks, and as such both are accounted for separately:

● The host financial liability is recognized at amortized cost applying the effective interest rate method;

● The embedded derivative convertible (American) call option is recognized at fair value using a binomial tree option pricing model whereby the fair value is based on the actual stock price and the estimated volatility of the Company's ADS on Nasdaq since the Company's IPO on November 4, 2021, and through the valuation date. The volatility measured at August 2, 2022, which was the closing date of the Innovatus debt facility, was 62.85% and at September 30, 2022 was 65.09%. Any changes to the fair value of the embedded derivative will be recognized through the statement of profit or loss.

***Kreos debt facility***

As part of the new debt facility with Innovatus, the Company's debt facility with Kreos for an outstanding principal amount of EUR 9 million has been fully repaid in cash as of September 30, 2022, for a total amount of $10.8 million. This repayment included the two convertible loans of €180,000 ($185,364) and €202,500 ($208,535) that were not converted by Kreos and that were entered into as part of amendments to the original Kreos debt facility.

The repayment did not include the derivative financial liability for the initial Kreos drawdown fee which had an estimated fair value on September 30, 2022 of $828,000 and is included in Other financial liabilities as a separate financial instrument valued at fair-value through statement of profit or loss.

The financial results largely related to the interest charges for the loan facility with Kreos Capital for a total of $206,000. The amortized cost is calculated using the effective interest method, which allocates interests and expenses at a constant rate over the term of the instrument. The debt extinguishment costs incurred amounted to $1.8 million and are included in the statement of profit or loss under Financial expenses.

**8. Financial result**

---

| | | |
|:---|:---|:---|
| *In thousands of USD* | *Jan-Sep <br> 2022* | *Jan-Sep <br> 2021* |
| Interests income | 86 | 11 |
| Interest on Kreos loan and <br> debt extinguishment costs | (1843) | (900) |
| Interests on Innovatus loan | (463) | 0 |
| Interests on other loans & leases | (234) | (220) |
| Fair value adjustments | (107) | (118) |
| Other financial loss | (220) | (99) |
| **Net financial results** | **(2781)** | **(1326)** |

---

The financial results primarily relate to interest charges and extinguishment expenses for the loan facility with Kreos Capital (as further detailed in Note 7) for a total amount of $1.8 million, as well as for the interest charges for the loan with Innovatus of $463,000, and for the interest charges on the lease liability for $234,000.

**9. Financial instruments and fair value**

The carrying value and fair value of the financial instruments as of September 30, 2022, and December 31, 2021, can be presented as follows:

---

| | | | |
|:---|:---|:---|:---|
| ***In thousands of USD***  | **As of**<br> **September 30,<br> 2022** | **As of**<br> **December 31, <br> 2021** | **Hierarchy** |
| **Assets**<br> *At amortized cost* | | | |
| Trade receivables  | 9540 | 4582 |  |
| Cash and cash equivalents | 27368 | 58498 |  |
| **Total financial assets** | **36908** | **63080** |  |
| **Liabilities** |  |  |  |
| *At fair value* |  |  |  |
| GPS prostate contingent consideration | 43777 | 0 | Level 3 |
| NovioGendix contingent consideration | 1558 | 1617 | Level 3 |
| Innovatus derivative financial instrument | 1044 | 0 | Level 3 |
| Kreos derivative financial instrument | 828 | 810 | Level 3 |
| **Subtotal financial liabilities at fair value** | **47207** | **2427** |  |
| *At amortized cost:* |  |  |  |
| Loans and borrowings | 35257 | 12092 | Level 2 |
| Lease liabilities | 3057 | 3464 |  |
| Trade payables | 12019 | 7455 |  |
| **Subtotal financial liabilities at amortized cost** | **50333** | **23011** |  |
| **Total financial liabilities** | **97540** | **25438** |  |

---

The fair value of the financial instruments has been determined on the basis of the following methods and assumptions:

● The carrying value of the cash and cash equivalents, the trade receivables, other current assets and the trade payables approximate their fair value due to their short-term character;

● The fair value of loans and borrowings applying the effective interest rate method approximates their carrying value (level 2).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Host
 financial liability of the Innovatus facility was obtained with a variable interest rate
 based upon the Prime Rate (with a floor of 4% and a margin of 4.25%).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Although
 the Kreos loan was obtained at the end of 2019 with a nominal fixed interest rate of 9.5%,
 the carrying value was considered to approximate their fair value considering:

§ Additional contractually agreed advance and post payments agreed upon with Kreos that have been integrated in the effective interest rate method;

---

| | |
|:---|:---|
| § | During 2020 and 2021, parties negotiated modification to the original agreement resulting in additional consecutive interest-only periods. As compensation for these modifications, part of the loan amounts became convertible as described in Note 7, however parties agreed to maintain nominal fixed interest rate in line with the initial agreement. |

---

§ Given repayment of the Kreos-loan during the third quarter of 2022, no fair value assessment done anymore as of September 30, 2022.

● Leases are measured at the present value of the remaining lease payments, using a discount rate based on the incremental borrowing rate at the commencement date of these leases. Their fair value approximates their carrying value.

● The fair value of contingent consideration payable to NovioGendix (presented in the yearend statement of financial position under "other non-current financial liabilities" and "other current financial liabilities") and GPS is based on an estimated outcome of the conditional purchase price/contingent payments arising from contractual obligations (level 3). These are initially recognized as part of the purchase price and subsequently fair valued with changes recorded through other operating income in the statement of profit or loss.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o For
 NovioGendix, the Company used a discount rate of 12.16%. The effect of the fair value measurement
 is $256,000 in the condensed consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The
 fair value of the contingent consideration payable with regard to the GPS acquisition is
 based on a probability-weighted average estimate based on multiple scenarios varying in timing
 and amount of earn-out payment. This probably-weighted estimated is then discounted to its
 net present value taking into account expected time when earn-out would become payable in
 2024, 2025 and 2026. This contingent consideration liability was initially recorded along
 with the purchase price allocation of this business combination as explained in Note 3. No
 subsequent fair value adjustments have yet been recorded as of 30 September 2022. The Company
 used a discount rate of 14.14%.

● The fair value of the derivative financial liabilities related to the initial Kreos drawdown fee of €630,000 initially is based upon the evolution of the share price of MDxHealth as well as the estimated probabilities that either payment at 150% or conversion will be requested by Kreos. Whereas share price of MDxHealth can be considered as a level 1 input, the other variable, being the probability assessment of possible scenarios should be considered as level 3 input. The fair value of the liability is estimated at September 30, 2022 at $828,000.

● The fair value of the derivative financial liabilities related to the Innovatus derivative call option (as detailed in Note 7) was performed using a binomial pricing model which takes into account several factors including the expected evolution in price of an ADS and are considered as level 3 input. The fair value of the liability is estimated at September 30, 2022 at $1.0 million.

 

*Fair value level 3 evolution*

 

*Initial drawdown fee convertible Kreos, Innovatus derivative call option, Noviogendix contingent consideration liability and GPS contingent consideration liability.*

 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *In thousands of USD<br> Balance at the closing date of* | ***September 30, 2022*** | ***September 30, 2022*** | ***September 30, 2022*** | ***September 30, 2022*** | ***December 31, 2021*** | ***December 31, 2021*** |
|  | **Kreos<br> convertible** | **NovioGendix<br> contingent<br> consideration** | **GPS<br> contingent<br> consideration** | **Innovatus<br> convertible** | **Kreos<br> convertible** | **Noviogendix<br> contingent<br> consideration** |
| **Beginning balance** | **810** | **1617** | **0** | **0** | **0** | **1599** |
| Reclassification <sup>(1)</sup> |  |  |  |  | 773 |  |
| Initial recognition |  |  | 43777 | 1026 |  |  |
| Effective interest rate adjustment | (27) | 197 |  |  |  | 194 |
| Foreign exchange rate impact / other | (86) |  |  |  | (59) |  |
| Fair value changes through profit and loss | 131 | (256) |  | 18 | 96 | (176) |
| **Balance at the closing date** | **828** | **1558** | **43777** | **1044** | **810** | **1617** |

---

*(1)* *Reclassification of the fair value of the derivative financial liability of the initial drawdown fee to be presented separately* 

 

*Fair value hierarchy*

The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:

● **Level 1**: quoted prices in active markets for identical assets and liabilities;

● **Level 2**: other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly; and

● **Level 3**: techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market data.

No financial assets or financial liabilities have been reclassified between the valuation categories during the period.

**10. Contingent consideration**

*Acquisition GPS test*

An additional aggregate earn-out amount of up to $70 million is to be paid by MDxHealth to Exact Sciences upon achievement of certain revenue milestones related to fiscal years 2023 through 2025, with the maximum earn-out payable in relation to 2023 and 2024 not to exceed $30 million and $40 million, respectively. On a preliminary basis, the contingent consideration has been assessed at $43.8 million which has been accounted for under other non-current liabilities as further detailed in Note 3. The liability recognized reflects a probability-weighted estimate at the current net present value which is expected to become payable. Future fair value adjustments to this contingent consideration liability will be recognized in the statement of profit or loss, after finalization of the purchase price allocation.

*NovioGendix*

 

The Company signed a sale and purchase agreement on September 18, 2015, to acquire all shares and voting interests of NovioGendix, an entity incorporated in The Netherlands.

Under the terms of the agreement, the Company is committed to pay up to $3.3 million subject to meeting certain milestones, be payable in six milestone payments. As of September 30, 2022, the Company has already paid $1.1 million.

The contingent consideration is valued at every reporting date and the change in fair value only relates to the time value of money, all other assumptions remained unchanged compared to December 31, 2021. This contingent liability has been evaluated at a fair-value of $1.6 million as of September 30, 2022 ($1.6 million at December 31, 2021) in our condensed interim consolidated statement of financial position, where $1,146,000 is included in "other non-current financial liabilities" and $412,000 in "other current financial liabilities" ($656,000 in "other non-current financial liabilities" and $961,000 in "other current financial liabilities" at December 31, 2021).

**11. Related party transactions**

There were no transactions to key management other than remuneration, warrants, and bonus, all of which is detailed in the Company's 2021 Annual Report. For the nine months ended September 30, 2022, total remuneration for key management and Directors was $1.4 million, with 2,200,000 warrants being granted.

There were no other related party transactions.

**12. Warrant plans**

On May 25, 2022, the General Assembly approved the creation of 5,000,000 "2022 Share Options" of which none have currently been granted as of September 30, 2022.

As of September 30, 2022, the Company granted a total of 3,603,000 warrants of the respectively "2019, 2021 and 2022 Share Options" to employees of the Company (respectively 43,000, 425,000 and 3,135,000 warrants). The warrants have been granted free of charge. Each warrant entitles its holder to subscribe to one common share of the Company at a subscription price determined by the board of directors, within the limits decided upon at the time of their issuance.

The warrants issued generally have a term of ten years as of issuance. Upon expiration of their term, the warrants become null and void. In general, the warrants vest in cumulative tranches of 25% per year, provided that the beneficiary has been employed for at least one year.

The fair value of each warrant is estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:

● The dividend return is estimated by reference to the historical dividend payment of the Company; currently, this is estimated to be zero as no dividends have been paid since inception

● The expected volatility was determined using the average volatility of the stock in Euronext Brussels over the last two years at the date of grant.

● Risk-free interest rate is based on the interest rate applicable for the 10-year Belgian government bond at the grant date

The model inputs for warrants granted during the period ended September 30, 2022, included:

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Grant date** | **6 May 2022** | **6 May 2022** | **4 August 2022** | **4 August 2022** | **3 August 2022** | **3 August 2022** | **3 August 2022** | **3 August 2022** | **4 August 2022** | **4 August 2022** |
| Exercise price | € | 0.75 | € | 0.798 | € | 0.684 | € | 0.684 | € | 0.797 |
| Expiry date |  | 31/03/2029 |  | 31/03/2029 |  | 31/03/2031 |  | 31/03/2032 |  | 31/03/2032 |
| Share price at grant date | € | 0.818 | € | 0.813 | € | 0.797 | € | 0.797 | € | 0.813 |
| Expected price volatility |  | 53.16% |  | 55.63% |  | 57.05% |  | 57.05% |  | 55.63% |
| Risk-free interest rate |  | 1.64% |  | 1.41% |  | 1.50% |  | 1.50% |  | 1.41% |

---

The total fair value of the granted warrant is estimated at $720 thousands following the underlying assumptions of the model.

**13. Statutory auditor's report to the Board of Directors of MDxHealth SA on the review of consolidated interim financial information for the nine-month period ended 30 September 2022**

**Introduction** 

We have reviewed the accompanying interim consolidated statement of financial position of MDxHealth SA as of 30 September 2022 and the related interim consolidated statements of comprehensive income, cash flows and changes in equity for the nine-month period then ended, as well as the explanatory notes. The Board of Directors is responsible for the preparation and presentation of this consolidated interim financial information in accordance with IAS 34 "Interim Financial Reporting", as adopted by the European Union. Our responsibility is to express a conclusion on this consolidated interim financial information based on our review.

**Scope of review**

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**Conclusion**

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated interim financial information is not prepared, in all material respects, in accordance with IAS 34 "Interim Financial Reporting", as adopted by the European Union.

Zaventem, January 20, 2023

BDO Bedrijfsrevisoren BV / BDO Réviseurs d'Entreprises SRL

Statutory auditor

Represented by Bert Kegels

**III. CORPORATE INFORMATION**

**Registered office**

MDxHealth SA has the legal form of a public limited liability company (société anonyme - SA / naamloze vennootschap - NV) organized and existing under the laws of Belgium. The company's registered office is located at CAP Business Center, Rue d'Abhooz 31, B-4040 Herstal, Belgium.

The company is registered with the Registry of Legal Persons (registre des personnes morales - RPM / rechtspersonenregister – RPR) under company number RPM/RPR 0479.292.440 (Liège).

**Listings**

Euronext Brussels: MDXH

NASDAQ: MDXH

**Financial year**

The financial year starts on 1 January and ends on 31 December.

**Statutory auditor**

BDO Bedrijfsrevisoren / Réviseurs d'entreprises BV/SRL

Da Vincilaan 9

1935 Zaventem

Belgium

**Availability of the Interim Report**

This document is available to the public free of charge and upon request:

MDxHealth SA - Investor Relations

CAP Business Center - Rue d'Abhooz, 31 – 4040 Herstal - Belgium

Tel: +32 4 257 70 21

E-mail: ir@mdxhealth.com

For informational purposes, an electronic version of the Interim Report 2022 is available on the website of mdxhealth at www.mdxhealth.com/investors/financials

## Exhibit 99.3

**Exhibit 99.3**

**UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION AS OF**

**AND FOR THE SIX MONTHS ENDED JUNE 30, 2022, AND FOR THE YEAR ENDED DECEMBER 31, 2021**

**Unaudited Pro Forma Financial Information**

On August 2, 2022, MDxHealth SA ("mdxhealth" or the "Company") entered into an asset purchase agreement (the "Acquisition") with Genomic Health, Inc., a subsidiary of Exact Sciences Corporation ("Exact Sciences"), to acquire the Oncotype DX® GPS (Genomic Prostate Score®) test from Exact Sciences.

Under the terms of the Acquisition, mdxhealth acquired the Oncotype DX GPS prostate cancer business of Exact Sciences for an aggregate purchase price of up to $100 million, of which an amount of $25 million was paid in cash and an amount of $5 million was settled through the delivery of 691,171 American Depositary Shares ("ADSs") of the Company, at a price per ADS of $7.23. Following the closing, an additional aggregate earn-out amount of up to $70 million is to be paid by mdxhealth to Exact Sciences upon achievement of certain revenue milestones related to fiscal years 2023 through 2025, with the maximum earn-out payable in relation to 2023 and 2024 not to exceed $30 million and $40 million, respectively.

The following unaudited condensed combined pro forma balance sheet as of June 30, 2022, gives effect to the Acquisition as if it had been completed as of June 30, 2022. The Acquisition was considered to be a business combination accounted for under International Financial Reporting Standards ("IFRS") acquisition method of accounting. Accordingly, the assets acquired, and liabilities assumed have been recorded at their estimated fair values at the date of the Acquisition. The purchase price has been allocated on a preliminary basis to the assets acquired and the liabilities assumed based upon estimates of their respective fair values, which are subject to potential adjustment upon finalization of the purchase price allocation.

The following unaudited condensed combined pro forma Statements of Operations for the six months ended June 30, 2022, and the year ended December 31, 2021, give effect to the Acquisition as if it had been completed on January 1, 2021.

The pro forma information has been prepared by our management and it may not be indicative of the results that actually would have occurred had the transaction been in effect on the dates indicated, nor does it purport to indicate the results that may be obtained in the future. The pro forma information is based on provisional amounts allocated by management to various assets and liabilities acquired and may be eventually different than currently presented.

The pro forma information has been developed from, and should be read in conjunction with, the special purpose financial statements and notes thereto of the Oncotype DX Prostate Score® Test ("GPS") filed herewith as Exhibit 99.1, and the Company's financial statements and notes thereto for the interim period ended June 30, 2022 filed on Form 6-K on August 26, 2022, as well as with the Company's Annual Report on Form 20-F for the year ended December 31, 2021, filed on April 25, 2022.

**Unaudited Combined Pro Forma Condensed Balance Sheet as of June 30, 2022**

**U.S. dollars in thousands**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| <br>**As of June 30, 2022** | **MDxHealth**<br>**Historical** | **GPS**<br>**Historical** | **Pro-forma transaction accounting adjustments** | **Pro-forma transaction accounting adjustments** | **Pro-forma transaction accounting adjustments** | **Pro-forma transaction accounting adjustments** | **Pro-forma**<br>**Combined** |
| **ASSETS** | | | | | | | |
| Goodwill |  |  | 29218 (D) |  |  |  | 29218 |
| Intangible assets | 3104 | 43398 | 1161 (D) |  |  |  | 47663 |
| Property, plant and equipment | 2364 |  |  |  |  |  | 2364 |
| Right-of-use assets | 3168 |  |  |  |  |  | 3168 |
| **Non-current assets** | **8636** | **43398** | **30379** | **-** | **-** | **-** | **82413** |
| Inventories | 2089 |  |  |  |  |  | 2089 |
| Trade receivables | 5036 |  |  |  |  |  | 5036 |
| Prepaid expenses and other current assets | 2724 |  |  |  |  |  | 2724 |
| Cash and cash equivalents | 40025 |  | (25000)(A) | (3458)(E) | 34280 (F) | (10172)(G) | 35675 |
| **Current assets** | **49874** | **-** | **(25000)** | **(3458)** | **34280** | **(10172)** | **45524** |
| **Total assets** | **58510** | **43398** | **5379** | **(3458)** | **34280** | **(10172)** | **127937** |
| **EQUITY** |  |  |  |  |  |  |  |
| Share capital | 128454 |  | 5000 (B) |  |  |  | 133454 |
| Issuance premium | 153177 |  |  |  |  |  | 153177 |
| Accumulated deficit | (262406) |  |  | (3458)(E) | (11)(F) | (1032)(G) | (266907) |
| Share-based compensation | 10986 |  |  |  |  |  | 10986 |
| Foreign currency translation reserves | (449) |  |  |  |  |  | (449) |
| **Total equity** | **29762** | **-** | **5000** | **(3458)** | **(11)** | **(1032)** | **30261** |
| **LIABILITIES** |  |  |  |  |  |  |  |
| Deferred tax liability | 129 |  |  |  |  |  | 129 |
| Loans and borrowings | 3291 |  |  |  | 33265 (F) | (1993)(G) | 34563 |
| Lease liabilities | 2454 |  |  |  |  |  | 2454 |
| Other non-current financial liabilities | 1934 |  | 43777 (C) |  |  | (810)(G) | 44901 |
| **Non-current liabilities** | **7808** | **-** | **43777** | **-** | **33265** | **(2803)** | **82047** |
| Loans and borrowings | 7760 |  |  |  |  | (7147)(G) | 613 |
| Lease liabilities | 870 |  |  |  |  |  | 870 |
| Trade payables | 9836 |  |  |  |  |  | 9836 |
| Other current liabilities | 2062 |  |  |  |  |  | 2062 |
| Other current financial liabilities | 412 |  |  |  | 1026 (F) | 810 (G) | 2248 |
| **Current liabilities** | **20940** | **-** | **-** | **-** | **1026** | **(6337)** | **15629** |
| **Total liabilities** | **28748** | **-** | **43777** | **-** | **34291** | **(9140)** | **97676** |
| **Total equity and liabilities** | **58510** | **-** | **48777** | **(3458)** | **34280** | **(10172)** | **127937** |

---

**Unaudited Combined Pro Forma Statement of Operations for the year ended December 31, 2021<br> and for the six months ended June 30, 2022**

**U.S. dollars in thousands**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **For the year ended December 31, 2021** | **MDxHealth<br> Historical** | **GPS<br> Historical** | **Pro-forma transaction accounting adjustments** | **Pro-forma transaction accounting adjustments** | **Pro-forma<br> Combined** |
| Services | 21937 | 37464 |  |  | 59401 |
| Licenses | 250 |  |  |  | 250 |
| Royalties and other revenues | 52 |  |  |  | 52 |
| **Revenues** | **22239** | **37464** | **-** | **-** | **59703** |
| Cost of goods & services sold | (11675) | (8084) |  |  | (19759) |
| **Gross Profit** | **10564** | **29380** | **-** | **-** | **39944** |
| Research and development expenses | (6673) | (2295) |  |  | (8968) |
| Selling and marketing expenses | (17744) | (31077) |  |  | (48821) |
| General and administrative expenses | (14149) |  | (3458)(E) |  | (17607) |
| Amortization |  | (5900) |  | 2929 (H) | (2971) |
| Other operating income, net | 1161 |  | - |  | 1161 |
| **Operating loss** | **(26841)** | **(9892)** | **(3458)** | **2929** | **(37262)** |
| Financial income | 11 |  |  |  | 11 |
| Financial expenses | (2172) |  | (1032)(G) | (2840)(I) | (6044) |
| **Loss before income tax** | **(29002)** | **(9892)** | **(4490)** | **89** | **(43295)** |
| Income tax | - |  |  |  | - |
| **Loss for the period** | **(29002)** | **(9892)** | **(4490)** | **89** | **(43295)** |
| **Loss for the period attributable to the parent** | **(29002)** | **(9892)** | **(4490)** | **89** | **(43295)** |
| **Loss per share attributable to parent in USD** |  |  |  |  |  |
| Basic and diluted | (0.24) |  |  |  | (0.34) |
| &nbsp;&nbsp;&nbsp;Weighted-average shares outstanding | 121935741 |  | 6911710 (J) |  | 128847451 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **For the six months ended June 30, 2022** | **MDxHealth<br> Historical** | **GPS<br> Historical** | **Pro-forma<br> transaction<br> accounting<br> adjustments** | **Pro-forma<br> Combined** |
| Services | 12975 | 18513 |  | 31488 |
| Licenses |  |  |  |  |
| Royalties and other revenues | 34 |  |  | 34 |
| **Revenues** | **13009** | **18513** | **-** | **31522** |
| Cost of goods & services sold | (7237) | (4702) |  | (11939) |
| **Gross Profit** | **5772** | **13811** | **-** | **19583** |
| Research and development expenses | (3585) | (1104) |  | (4689) |
| Selling and marketing expenses | (9848) | (15512) |  | (25360) |
| General and administrative expenses | (9636) |  |  | (9636) |
| Amortization |  | (2950) | 1465 (H) | (1485) |
| Other operating income, net | 274 |  | - | 274 |
| **Operating loss** | **(17023)** | **(5755)** | **1465** | **(21313)** |
| Financial income | 27 |  |  | 27 |
| Financial expenses | (1107) |  | (1478)(I) | (2585) |
| **Loss before income tax** | **(18103)** | **(5755)** | **(13)** | **(23871)** |
| Income tax | (1) |  |  | (1) |
| **Loss for the period** | **(18104)** | **(5755)** | **(13)** | **(23872)** |
| **Loss for the period attributable to the parent** | **(18104)** | **(5755)** | **(13)** | **(23872)** |
| **Loss per share attributable to parent in USD** |  |  |  |  |
| Basic and diluted | (0.12) |  |  | (0.15) |
| &nbsp;&nbsp;&nbsp;Weighted-average shares outstanding | 155969226 |  | 6911710 (J) | 162880936 |

---

**1. Basis of Presentation**

On August 2, 2022, MDxHealth SA ("mdxhealth" or the "Company") entered into an asset purchase agreement (the "Acquisition") with Genomic Health, Inc., a subsidiary of Exact Sciences Corporation ("Exact Sciences"), to acquire the Oncotype DX® GPS (Genomic Prostate Score®) test from Exact Sciences.

The unaudited pro forma condensed combined balance sheet as of June 30, 2022, gives effect to the Acquisition as if it had occurred on June 30, 2022. The unaudited pro forma condensed combined statements of operations for the year ended December 31, 2021, and for the six months ended June 30, 2022, are presented as if the Acquisition had occurred on January 1, 2021.

The unaudited pro forma condensed combined financial information was prepared using the acquisition method of accounting, based on the historical financial statements of mdxhealth and the special purpose financial statements of the Oncotype DX Prostate Score® Test.

**2. Preliminary Purchase Price Allocation**

The Acquisition was accounted for under the purchase method of accounting and is being treated as a business combination in accordance with IFRS. The purchase price was preliminarily allocated based on the estimated fair value of net assets acquired and liabilities assumed at the date of the acquisition. The preliminary purchase price allocation is subject to further refinement and may require adjustments to arrive at the final purchase price allocation. The Company expects to finalize the purchase price allocation within the context of its 2022 yearend reporting.

The acquisition consideration was comprised of (in thousands):

---

| | |
|:---|:---|
| Cash | $25000 |
| Stock | 5000 |
| Contingent consideration (1) | 43777 |
| &nbsp;&nbsp;&nbsp;Total acquisition consideration | $73777 |

---

(1) Following the closing, an additional
aggregate earn-out amount of up to $70 million is to be paid by mdxhealth to Exact Sciences upon achievement of certain revenue milestones
related to fiscal years 2023 through 2025, with the maximum earn-out payable in relation to 2023 and 2024 not to exceed $30 million and
$40 million, respectively. On a preliminary basis the contingent consideration has been assessed at $43.8 million. The liability recognized
reflects a probability-weighted estimate at the current net present value at the date of acquisition which is expected to become payable
Future fair value adjustments to this contingent consideration liability will be recognized in the statement of profit or loss, after
finalization of the purchase price allocation.

On a preliminary basis, and until the purchase price allocation has been finalized, the purchase price in excess of the fair value of net assets acquired (refer to adjustment (d) in Note 3, Pro Forma Transaction Accounting Adjustments), has been considered as residual Goodwill. Goodwill will not be amortized but will be tested for impairment at least annually or whenever certain indicators of impairment are present. If, in the future, it is determined that goodwill is impaired, an impairment charge would be recorded at that time. Should the final purchase price allocation result in additional intangible assets to be recognized, Goodwill will be decreased accordingly, and amortization charges will be applied to the intangible assets.

**3. Pro Forma Transaction Accounting Adjustments**

For the purpose of the pro-forma combined financial information, the Company considers the valuation of the intangible assets as preliminary value. The final purchase price allocation might result in material changes to recognized intangibles assets and its related useful lives, which in that case could also result in a change in amortization charges on these intangible assets, recognized contingent consideration liability, related deferred tax impacts on the purchase price allocation, and the residual goodwill amount.

**(A)** To record the cash paid for assets
acquired in the Acquisition

**(B)** To record the issuance of 691,171
American Depositary Shares ("ADSs") of the Company, at a price per ADS of $7.23 as part of the Acquisition

**(C)** To record contingent consideration
of the net present value of expected future earnout payments (as described in Note 2, Preliminary Purchase Price Allocation)

**(D)** To record purchase price in excess
of fair value of net assets acquired, based on a preliminary purchase price allocation:

---

| | |
|:---|:---|
| Cash | $25000 |
| Stock | 5000 |
| Contingent consideration | 43777 |
| &nbsp;&nbsp;&nbsp;Total acquisition consideration | $73777 |
| Net book value as of June 30, 2022 in the special purpose financial statements of the Oncotype DX Prostate Score® Test | 43398 |
| Fair value adjustment to the net book value of the intangible asset, based on preliminary purchase price allocation | 1161 |
| Goodwill | $29218 |

---

**(E)** To record costs associated with
the Acquisition

**(F)** To record the debt facility with
Innovatus associated with the Acquisition. The Innovatus debt facility is considered a hybrid financial instrument, which includes a
host financial liability and an embedded derivative call option to convert up to 15% of the aggregate outstanding principal into equity
at a fixed rate of $11.21 per ADS. The host financial liability, which is accounted for at amortized cost applying the effective interest
rate method, is recorded under Loans and borrowings (non-current) while the derivative financial liability is recorded under Other non-current
financial liabilities

**(G)** To record the extinguishment of
the Kreos Capital debt facility, replaced by the new debt facility with Innovatus as well as reclassification of remaining liability
related to the derivative financial liability for the initial Kreos drawdown fee from non-current to current

**(H)** To adjust estimated amortization
charges of the intangible asset resulting from preliminary fair value assessment, with an estimated remaining useful life of 15 years

**(I)** To adjust financial expenses to
reflect higher financial charges associated with the Innovatus debt facility which replaced previously accounted for financial charges
related to the Kreos debt facility. The Innovatus debt facility accrues interest at a floating per annum rate equal to the sum of (a)
the greater of (i) the prime rate published in The Wall Street Journal in the "Money Rates" section or (ii) 4.00%, plus (b)
4.25%, and require interest-only payments for the initial four years. A change in the effective interest rate of 0.125% would result
in an annual change in interest charges of approximately $38,000.

**(J)** To reflect the issuance of shares
as part of the Acquisition